The AST/ALT (De Ritis) ratio predicts clinical outcome in pancreatic cancer patients treated with first-line nab-paclitaxel and gemcitabine: post-hoc analysis of an Austrian multicenter, non-interventional study

J. Riedl; F. Posch; G. Prager; W. Eisterer; L. Öhler; S. Thamer; K. Wilthoner; A. Petzer; P. Pichler; E. Hubmann; T. Winder; S. Burgstaller; M. Korger; J. Andel; R. Greil; M. Pecherstorfer; K. Philipp-abbrederis; A. Djanani; B. Gruenberger; F. Längle; E. Wöll; A. Gerger

doi:10.1093/annonc/mdz155.285

The AST/ALT (De Ritis) ratio predicts clinical outcome in pancreatic cancer patients treated with first-line nab-paclitaxel and gemcitabine: post-hoc analysis of an Austrian multicenter, non-interventional study

J. Riedl, F. Posch, G. Prager, W. Eisterer, L. Öhler, S. Thamer, K. Wilthoner, A. Petzer, P. Pichler, E. Hubmann, T. Winder, S. Burgstaller, M. Korger, J. Andel, R. Greil, M. Pecherstorfer, K. Philipp-abbrederis, A. Djanani, B. Gruenberger, F. LängleE. Wöll, A. Gerger

Publikation: Beitrag in Buch/Bericht/Konferenzband › Beitrag in Konferenzband

Originalsprache	Englisch
Titel	Annals of Oncology
Seiten	iv78
DOIs	https://doi.org/10.1093/annonc/mdz155.285
Publikationsstatus	Veröffentlicht - 01 Juli 2019

Zugriff auf Dokument

10.1093/annonc/mdz155.285Lizenz: Sonstige

https://linkinghub.elsevier.com/retrieve/pii/S0923753419308026

Dieses zitieren

Riedl, J., Posch, F., Prager, G., Eisterer, W., Öhler, L., Thamer, S., Wilthoner, K., Petzer, A., Pichler, P., Hubmann, E., Winder, T., Burgstaller, S., Korger, M., Andel, J., Greil, R., Pecherstorfer, M., Philipp-abbrederis, K., Djanani, A., Gruenberger, B., ... Gerger, A. (2019). The AST/ALT (De Ritis) ratio predicts clinical outcome in pancreatic cancer patients treated with first-line nab-paclitaxel and gemcitabine: post-hoc analysis of an Austrian multicenter, non-interventional study. in Annals of Oncology (S. iv78) https://doi.org/10.1093/annonc/mdz155.285

@inproceedings{fd6a564470904194b215f9684a73496f,

title = "The AST/ALT (De Ritis) ratio predicts clinical outcome in pancreatic cancer patients treated with first-line nab-paclitaxel and gemcitabine: post-hoc analysis of an Austrian multicenter, non-interventional study",

author = "J. Riedl and F. Posch and G. Prager and W. Eisterer and L. {\"O}hler and S. Thamer and K. Wilthoner and A. Petzer and P. Pichler and E. Hubmann and T. Winder and S. Burgstaller and M. Korger and J. Andel and R. Greil and M. Pecherstorfer and K. Philipp-abbrederis and A. Djanani and B. Gruenberger and F. L{\"a}ngle and E. W{\"o}ll and A. Gerger",

note = "Abstract",

year = "2019",

month = jul,

day = "1",

doi = "10.1093/annonc/mdz155.285",

language = "English",

pages = "iv78",

booktitle = "Annals of Oncology",

}

Riedl, J, Posch, F, Prager, G, Eisterer, W, Öhler, L, Thamer, S, Wilthoner, K, Petzer, A, Pichler, P, Hubmann, E, Winder, T, Burgstaller, S, Korger, M, Andel, J, Greil, R, Pecherstorfer, M, Philipp-abbrederis, K, Djanani, A, Gruenberger, B, Längle, F, Wöll, E & Gerger, A 2019, The AST/ALT (De Ritis) ratio predicts clinical outcome in pancreatic cancer patients treated with first-line nab-paclitaxel and gemcitabine: post-hoc analysis of an Austrian multicenter, non-interventional study. in Annals of Oncology. S. iv78. https://doi.org/10.1093/annonc/mdz155.285

TY - GEN

T1 - The AST/ALT (De Ritis) ratio predicts clinical outcome in pancreatic cancer patients treated with first-line nab-paclitaxel and gemcitabine: post-hoc analysis of an Austrian multicenter, non-interventional study

AU - Riedl, J.

AU - Posch, F.

AU - Prager, G.

AU - Eisterer, W.

AU - Öhler, L.

AU - Thamer, S.

AU - Wilthoner, K.

AU - Petzer, A.

AU - Pichler, P.

AU - Hubmann, E.

AU - Winder, T.

AU - Burgstaller, S.

AU - Korger, M.

AU - Andel, J.

AU - Greil, R.

AU - Pecherstorfer, M.

AU - Philipp-abbrederis, K.

AU - Djanani, A.

AU - Gruenberger, B.

AU - Längle, F.

AU - Wöll, E.

AU - Gerger, A.

N1 - Abstract

PY - 2019/7/1

Y1 - 2019/7/1

U2 - 10.1093/annonc/mdz155.285

DO - 10.1093/annonc/mdz155.285

M3 - Contribution to conference proceeding

SP - iv78

BT - Annals of Oncology

ER -